Page de couverture de Adopting the Evolving Management of HR+/HER2-mBC into Practice

Adopting the Evolving Management of HR+/HER2-mBC into Practice

Adopting the Evolving Management of HR+/HER2-mBC into Practice

Auteur(s): Annenberg Center for Health Sciences
Écouter gratuitement

À propos de cet audio

 Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.Annenberg Center for Health Sciences Hygiène et mode de vie sain Troubles et maladies
Épisodes
  • Molecular and Tumor Profiling

    Molecular and Tumor Profiling
    Apr 9 2025

    Molecular and Tumor Profiling
    Voir plus Voir moins
    23 min
  • Background and Scope for Management of Patients with HR+/HER2- mBC

    Background and Scope for Management of Patients with HR+/HER2- mBC
    Apr 9 2025

    Background and Scope for Management of Patients with HR+/HER2- mBC
    Voir plus Voir moins
    7 min
Pas encore de commentaire